Loading...
Market
What Will Be Ultragenyx's Next Major Step with Gene Therapy by Nov 30, 2024?
5
Resolution / Starting Odds
Seek further regulatory approvals • 33%
Begin commercial production • 33%
Partner with another company for distribution • 34%
Ultragenyx official announcements and press releases
Story
Ultragenyx ($RARE) Gene Therapy for Rare Liver Ailment Succeeds in Late-Stage Trial
May 30, 2024, 08:51 PM
Ultragenyx's gene therapy for a rare liver ailment has succeeded in a late-stage trial. The therapy, which aims to treat a condition affecting the liver, has shown promising results, marking a significant milestone for the company. The news, reported on May 30, 2024, was covered by multiple sources, including Jason Mast for Stat News. Ultragenyx is listed under the ticker symbol $RARE.
View original story
Similar markets
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
FDA approval for another drug • 33%
Major partnership announcement • 33%
No major milestone • 33%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
Yes • 50%
No • 50%
